FierceBiotech's executive breakfast in Boston looms

We're just two weeks away from our panel discussion in Boston on the latest trends in clinical trials and I'm happy to say we've got a great crowd of biopharma execs already registered for the event. More than 130 trial-minded individuals have arranged to attend the session. And I'd encourage you to come along for a meaty executive breakfast covering issues that strike right at the heart of drug development.

On the morning of Oct. 27th I'll be moderating a discussion with AstraZeneca's Frederic Sax, Tal Zaks from Sanofi, Cubist's Santosh Vetticaden and Bill Slichenmyer from AVEO to discuss the best ways to improve your odds and stretch your budget when it comes to clinical trial design and execution. Boston has been a hotbed of innovation in the biopharma industry and it's the perfect spot to host one of our public events. Each one of our experts has years of experience planning and executing drug trials.

So if you're in Boston, or plan to be there October 27th, I hope you'll join us for breakfast. Click here to register. -- John Carroll

Suggested Articles

All 12 members of an FDA advisory committee voted to recommend the approval of teprotumumab for a rare, autoimmune eye disease.

Early data out of former Fierce 15 winner Gritstone Oncology have been heralded as a big win for the early-stage biotech by analysts.

Biogen will drop work on gosuranemab in progressive supranuclear palsy but continue on in Alzheimer's.